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Abstract 
Objective: To evaluate the effect of simple acupressure protocol in LIV3, LI4 and placebo 
points on the quality of life (QOL) in women with premenstrual syndrome (PMS). 
Method: This paper reports a randomized, single blinded clinical trial. 97 participants 
(students in of Hormozgan University of Medical Sciences, Iran) with PMS were allocated to 
three groups to receive 20 minutes acupressure on different acupoints for 14 days before 
menstruation for three consecutive menstrual cycles (training and then two cycles self applied 
acupressure).The acupoints were LIV3 and LI4; one group received acupressure at a placebo 
point. Each participant completed the PSST scale (to determine PMS severity), HADS scale 
(for depression and anxiety), and quality of life SF12.  
Results: The number of people with moderate/severe PMS decreased in LIV3 and LI4 
acupressure groups by the second and third cycles compared with the placebo group 
(p<0.04). 
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Moreover, depression and anxiety scores significantly decreased in the LIV3 and LI4 groups 
by the second and third cycles compared with the placebo group (p<0.05).Analyzing the 
score of SF12 fields in the second and third cycles showed a significant difference in all 
dimensions between the intervention and placebo groups. There was no significant difference 
between LIV3 and LI4 acupressure groups in decrease of PMS symptoms, anxiety and 
depression and improving SF12scores (p<0.05). 
Conclusion: Performing the simple acupressure protocol at LIV3 and LI4 is an effective 
method to decrease the severity of PMS symptoms, anxiety and depression, and to improve 
the QOL. Pressure at LIV3 and LI4 appear to be equally effective. 
Key words: Premenstrual syndrome, Acupressure, Quality of life. 
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Introduction 
Premenstrual syndrome (PMS) is the periodic recurrence of physical, cognitive, and 
behavioral symptoms which occurs during the luteal phase of menstruation and ends a few 
days' afterbleeding starts. 70-90 percent of women show different levels of PMS signs among 
which 20-40 percent result in dysfunction in daily activities(1). In addition, PMS results in 
increasing adverse educational, economic (absence of the work), and social (committing 
murder and crime) consequences, as well as decreasing quality of life (QOL)(2). 
The cause of PMS is multi-factorial and no cure is known. Therefore, only symptomatic 
treatment is available. Medical treatments include selective serotonin reuptake inhibitors 
(SSRIs) and oral contraceptives (3). Complementary and alternative medicine is treatment 
methods proposed to diminish the severity of PMS symptoms(4). 
In complementary and alternative medicine, the etiology and pathogenesis of PMS can be 
explained as stagnation of energy in the liver and pathological changes in energy level (qi) 
which affect other body organs. By regulating the liver function, one's mind and mood is 
regulated then. Therefore, when the liver qi is stagnated and cannot move easily, one's mind 
and mood is disturbed and psychological and emotional signs appear(4). 
It's proposed several acupoint may be used for alleviate of PMS including 
GV24(6),LI4(6),LR3(6),SP6(6),GV20(7),CV3,4,6(7),PC6(7),GB34(7),BL23(7),Shenman(7),
CV9(8),CV17(9),A5,6,8,12,16,18(10),N18(10),F6(10),GV24(11),ST36(12),BL18,19,20,21,2
2,47,48,49,50,51,52(13). However, there are no studies done to evaluate the effects of 
acupressure on PMS symptoms. The purpose of this study was to evaluate the effect of 
acupressure in the third hepatic (taichung), fourth large intestine (HUGO), in comparison 
with placebo acupressure, on PMS symptoms and QOL in females with PMS.  
Methods 
a) Design and data collection 
The present study is a randomized single blinded clinical trial; we recruited students through 
advertisements in the campus accommodation of Hormozgan University of Medical Sciences, 
Iran. Sampling and allocation to groups was randomized and the sample size calculated at 30 
per each group with α=0.5, 1-β=0.8, and S2p=2.22. Except several cases with loss to follow 
up, treatment compliance for the three cycles was 100%. There are not any reported adverse 
4 
 
effects. The researcher telephoned the participants to remind them (five days to menstruation, 
every day) of the timing of the interventions and follow-up visits during all two cycles. 
It should be noted that the researcher (FB) had been trained in acupressure techniques and 
manipulation of related acupoints from a Traditional Chinese Medicine (TCM) specialist for 
20 sessions at a period of four months.  
After approval by the ethics committee of Hormozgan University of Medical Science in Iran, 
all the students in Hormozgan University of Medical Science received a pamphlet with 
general information about PMS and acupressure. Then, participants who were eligible 
entered the study after referring to researcher and giving the written consent. 
Two training sessions in the accommodation selected on the field of PMS pathology, 
treatment methods, and introducing acupressure. Students only did the training if they were 
selected to the study. 
b) Recruitment of participants 
Inclusion criteria were age18-45, menstruation cycle intervals 21-35 days, lack of infectious 
skin diseases, absence of acute rheumatoid arthritis, absence of lesions or dermatitis at the 
acupressure sites, absence of visual or auditory impairment, avoidance of NSAIDs or other 
analgesics three hours before starting the intervention, absence of severe depression and 
anxiety(based on HADs questionnaire), absence of severe psychological tension during the 
last  six months(loss of relatives, surgery), absence of heart disease, renal disorder, diabetes, 
asthma, hypo/hyper thyroidism, respiratory disorders, lack of any genital disease, having 
moderate to severe PMS according to the score of PSST questionnaire [one item of the 
questions number 1-4 scored moderate to severe; in addition, at least four items are scored 
moderate to severe from question 1 to 14; one item is scored moderate to severe in the part of 
impact on life (the 5 latter questions)]. 
c) Acupressure  
First cycle: Participants were randomly divided into the study groups using a table of random 
numbers, and trained how to apply pressure on the points of LIV3, LI4, and the placebo 
(which is not in the line of meridian). Participants were blinded to their allocation to the 
intervention groups. 
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 The LIV3 or third hepatic acupoint is of hepatic meridian which is located at dorsal surface 
of the foot between the first and second toes at the point of bones junction(14) (Figure 3). The 
LI4 or long intestine acupoint is located at the dorsal surface of the hand between thumb and 
index finger approximately at the middle of the second metacarpal bone(14) (Figure 2). The 
placebo point is located at dorsal surface of the foot between the third and the forth toes 
which is not in the line of meridian (Figure 4). As bleeding started, each of participants 
completed the Premenstrual Symptoms Screening Tool (PSST), Hospital Anxiety and Depression 
Scale (HADS), and SF12 questionnaires. In this cycle, only participation's division and 
questionnaire completion were done. 
Second cycle: participants laid down in the supine position (in order to avoiding hypotension 
and dizziness). At first, the participant sat down for 10-15 minutes to adapt to the room 
temperature. All the windows and the doors were closed and nobody was allowed to inter the 
room to avoid the impact of external stimulus. Applying pressure on the given points of the 
right foot started 14 days before menstruation at the time period of 19-21 o'clock taking 20 
minutes and it was repeated daily until the bleeding started. The pressing pattern consisted of 
two minutes harmonic pressure (one minute in a clockwise direction and one minute in a 
counter clock-wise direction). In the next two minutes the researcher manipulated the point 
without any pressure in order that meridian stimulation did not stop. Applying pressure 
continued until the participant felt a light pain in the acupoint. Pressing stopped and the 
amount of color change in the nail was observed as a marker and showed to the participant to 
know how much pressure should herself apply in the next cycle. In addition, the acupressure 
technique for the given point was taught to the subjects. When menstrual bleeding started, 
PSST, SF12, and HADs questionnaires were completed by each participant. 
Third cycle: As shown in the previous cycle, the participant herself applied pressure on the 
given point in sitting position by the third cycle. At the onset of bleeding, each participant 
was requested to complete PSST, SF12, and HADs questionnaires. 
 The researcher telephoned the participants to remind them (five days to menstruation, every 
day) of the timing of the interventions and follow-up visits during all two cycles. 
Measures 
1. PSST questionnaire: this questionnaire turns diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSMIV) classified criteria to a rating scale based on the PMS 
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severity. This questionnaire indicates disease severity and the impact of PMS symptoms 
on the individual's life (15). PSST has 19 questions in two parts, 14 questions related to 
the mood, body, and behavior and five questions based on the potential impact of these 
symptoms on individual’s life. The answers range across a Likert spectrum (never, mild, 
moderate and severe) scoring zero to three respectively. The validity and reliability of the 
questionnaire are recognized (16). 
2. QOL: SF12 evaluated quality of life. This includes 12 questions related to the eight 
domains of vitality, physical functioning, bodily pain, general health perceptions, physical 
role functioning, emotional role functioning, social role functioning, mental health. The 
scoring was done based on the RAND system from zero to 100. The score of each domain is 
obtained by aggregating the question scores of every domain and dividing the resulting 
number by the number of questions same domain. Higher score indicates better QOL(17). 
The validity and reliability of the questionnaire are approved(18).  
3. Depression and anxiety: the HADs questionnaire contains 14 questions. Seven questions 
on the domain of depression and seven questions for the field of anxiety. Each answer scored 
zero to three based on likert spectrum, and the total score of both fields are 0-21. The validity 
and reliability of the questionnaire are approved(19).  
4. Body mass index (BMI) was measured by weight (kg)/Height
2
 (m). 
5. Socio-economic status: The number of years of formal education of each participant was 
taken as an indicator of socio-economic status.  
d) Data analysis 
Data analysis were done using descriptive statistics (frequency, percent, mean, standard 
deviation), kruskawallis (to analyze qualitative variable), and ANOVA (to analyze quantative 
variables). Intergroup comparison was done using the Sheffe test. Data were analyzed using 
Statistical Package for the Social Sciences 21.0 (SPSS Inc., Chicago, IL, USA). Significance 
level of p<0.05 was considered. 
  
7 
 
Results 
The process of allocating participants during 2015 -2016 is shown in Figure 1. 
a) Sample characteristics 
90 participants completed treatment and follow-up, and were included in the analysis. There 
was no significant difference between groups in age, BMI, education, the score of QOL 
fields, depression and anxiety scores (P>0.05) (Table 1). 
b) Severity of PMS, depression and anxiety 
Table 2 shows a significant decrease in the number of PMS symptoms (moderate to severe) 
according to PSTT in LIV3 (23 vs. 21) and LI4 (18 vs. 16) compared with the placebo group 
(30 vs. 29) after intervention (second and third cycles) (P<0.05). 
Moreover, there was a significant difference in depression score in the second and third 
cycles in LIV3 (11.50±2.16 vs. 10.17±0.46) and LI4 (11.60±2 vs. 10.36±2.23) compared with 
the placebo group (12.33±0.72 vs. 11.46±2.54) (P<0.05) (Table 3).  
There was a significant difference in anxiety score in the second and third cycles in LIV3 
(9.73±1.52 vs. 9.43±1.13) and LI4 (10.20±2.48 vs. 10.90±6.33) compared with the placebo 
group (9.22±2.02 vs. 8.72±2.90) (P<0.05) (Table 3). 
The Sheffe test showed no significant difference between LIV3 and LI4 groups in severity of 
PMS, depression and anxiety (P>0.05).  
c) Quality of life 
There was a significant difference between groups in all fields of quality of life (P<0.05). 
Table 4 shows that QOL score was better in LIV3 and LI4 acupressure groups compared with 
the placebo.  
The Sheffe test showed no significant difference between LIV3 and LI4 groups in QOL 
(P>0.05). 
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Discussion 
The current study is the first study which evaluates the effect of applying acupressure in two 
separate acupointsLIV3 and LI4 in comparison with placebo on QOL in women with PMS. 
The results show the number of PMS cases (moderate/severe) according to PSST scale 
significantly decreased in acupressure groups compared with the placebo in the second and 
third menstrual cycles. In other words, the severity of PMS symptoms according to PSST 
scale dramatically decreased in acupressure groups. In a study of Fong etal (date) the PMS 
signs and symptoms improved in acupuncture groups of LR3, CV4, 6, SP6, GV24 acupoints 
in comparison with the control group (using herbal medications)(21).Habek et al reported that 
PMSsymptoms significantly decreased (p<0.001) in acupuncture groups (Shemun, BT23, 
GB39, PC6, CV3,4,10, LK3, LI4 and GV2acupoints) compared with the control group 
(acupuncture sham)(22). However, acupuncture is associated with some complications such 
as pain, and bleeding at the puncture site, damage to internal organs, and increasing the risk 
of infectious disease such as hepatitis and AIDS. Acupressure has no side effects and 
disadvantages even in the case of incomplete performance. Acupressure is a non-invasive 
treatment method, easy to apply, and it can be done by individual. 
Xuand Sun(2006) showed that PMS severity was significantly decreased in intervention 
group (acupuncture in the acupoints of GV3,4,5,6,7,8, BL18,23,47,49,50,52for 14 days 
before menstruation during three cycles) in comparison with the control group 
(Medroxyprogestron acetate 6 µgr/ day from 16
th
d to 25
th
 day ofmenstrual cycle ) 
(p<0.001)(23). Although, in our study intervention done by individuals themselves in the 
third cycle and only one acupoint is allocated to each intervention group in order to avoid 
participant’s confusion. 
Acupressure and acupuncture provide more relaxation and less tension. Moreover, 
acupressure decreases blood levels of serotonin, increases endorphins and neuro-peptide Y; 
stimulates the nerves located inmuscle and other tissues, and helps release endorphins and 
other neuro-hormones. Acupressure can also change the pain process in the brain and spinal 
cord, and reduce information by stimulating the release of vascular and immunity factors(22).  
In this study, the QOL score was better in all subscales in acupressure groups compared with 
the control group which is probably due to the improved physical and mental health in the 
acupressure groups. This is the first study to show this finding. Moreover, the level of 
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depression and anxiety in the acupressure groups significantly decreased compared with the placebo 
group. This finding was similartothe results of the previous studies reporting that acupressure reduces 
depression in hemodialysis patients (25), chronic pulmonary obstruction disease(26), and chronic 
knee pain in the patients of elderly care centers(27). Acupoint stimulation increases the release of 
serotonin and endorphins, and regulates the level of serum cortisol. These hormonal changes reduce 
depression and result in more relaxation which directly changes the mechanisms leading to 
depression(28).  
The strengths of the present study include following-up the subjects during three consecutive 
menstrual cycles, considering the placebo group, and applying pressure on the placebo point 
similar to the intervention groups in order to continuous meridian stimulation. The present 
study had some limitations. Oral, written, and practical training were used in this study to 
help subjects identify the location of acupoint and learn the pressing technique. We studied 
the students of one university while the results may vary with the results obtained from young 
women with lower education level or other ethnic groups in other universities. Randomized 
studies with larger sample size and longer follow-up period would improve the existing 
knowledge on the benefits and mechanism of acupressure in PMS.  
Funding  
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Figure 1: flow chart of study 
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Figure 2: Location of LI4 point 
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Figure 3: Location of LIV3 point 
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Figure 4: Location of placebo point 
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Table1: Demographic and baseline characterizes of participants 
 
**Mean±SD 
physical functioning (PF), role limitations due to physical problems (29), bodily pain (BP), 
general health perception (GH), social functioning (SF), role limitations due to emotional 
problems (RE), vitality (VT), and mental health (MH), mental subscale component (MSC), 
physical subscale component ( PSC) 
  
 
Variable 
Group P 
value 
placebo Liv3 LI4 
Age (years)** 22.06±1.86 21.77±1.18 22.03±1.97 0.79 
Education (years)** 15.68±0.96 16±1.2 15.23±0.89 0.8 
BMI** 19.598±2.41 19.45±2.18 19.70±3.07 0.15 
 
 
HADS** 
Anxiety  10.79±2.04 10.72±1.25 10.36±7.70 0.7 
Depression 11.31±1.78 11.51±1.24 11.36±7.86 
 
S
F
1
2
 
d
o
m
ai
n
s*
*
 
PF 63.33±22.10 66.96±25.39 65±23.67 0.09 
RP 63.79±31.04 67.02±12.49 62.08±23.32 0.47 
RE 71.98±26.01 74.16±13.10 62.50±25.21 0.51 
VE 75.83±12.25 69.13±23.60 69.83±12.45 0.87 
SF 45.50±12.01 50±25.87 48.33±23.42 0.27 
BP 65.34±20.61 67.50±12.01 68.33±23.61 0.6 
GH 65±16.86 70.55±24.75 69.16±20.43 0.52 
MH 70.86±24.76 66.66±7.14 64.58±18 0.07 
MSC 63.22±9.44 65.17±18.47 68.64±15.53 0.53 
PSC 66.66±8.42 65.49±9.13 66.56±12.23 0.64 
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Table2: PSST scores in the second &third cycles between groups 
 
 
 
**ANOVA 
*Mean±SD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable* 
Group  
P value** Placebo Liv3 LI4 
S
ec
o
n
d
 
cy
cl
es
 NO/Mild _ 6(24.15) 12(40) 0.001 
Moderate/severe 30(100) 23(79.3) 18(60) 
T
h
ir
d
 
cy
cl
es
 NO/mild 1(3.3) 9(31) 14(46.7) <0.001 
Moderate/severe 29(96.7) 21(72.45) 16(53.3) 
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Table 3: HADS Scores in the second & third menstrual cycles between groups 
 
Variable** 
 
groups  
P value* placebo Liv3 LI4 
S
ec
o
n
d
 
C
y
cl
e 
Anxiety 9.22±2.02 9.73±1.52 10.20±2.48 <0.001 
Depression 12.33±0.72 11.50±2.16 11.60±2 0.02 
T
h
ir
d
 
C
y
cl
es
 Anxiety 8.72±2.90 9.43±1.13 10.90±6.33 <0.001 
Depression 11.46±2.54 10.17±0.46 10.36±2.23 0.05 
 
*ANOVA 
**Mean± SD 
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Table 4: quality of life subscales in the second & third menstrual cycles between groups. 
 
 
Variable** 
 
 
groups 
 
P value* 
placebo Liv3 LI4 
 
S
ec
o
n
d
 
C
y
cl
e 
*
*
 
PF 75±32.04 65.83±23.19 64.83±32.48 0.01 
RF 70.25±25.11 85.83±15.65 82.50±21.52 0.01 
RE 63.33±25.41 78.75±10.03 63.33±25.41 0.01 
VE 56.25±25.11 65.83±15.65 62.50±21.52 0.04 
SF 51.55±14.52 57.93±28.83 55±25.08 0.05 
BP 60.34±21.66 81.66±11.24 87.50±18.74 0.01 
GH 69.50±28.35 78.33±10.45 76±21.21 0.01 
MH 50.89±13.99 54.16±5.99 52.50±11.08 0.04 
PSC 70.47±18.23 78.68±8.75 76.29±17.22 0.05 
MSC 53.79±12.18 62.50±6.78 63.33±17 0.03 
T
h
ir
d
 
C
y
cl
es
*
*
 
PF 65.83±28.97 80.17±27.04 94.16±12.40 <0.001 
RP 65.66±245.98 89.39±28.65 90±9.5 <0.001 
RE 67±23.11 72.41±11.87 70.08±32.15 0.01 
VE 58.62±28.56 59.16±12.60 61.66±6.04 0.04 
SF 29.16±10.75 34.16±24.98 33.31±26.78 0.05 
BP 74.83±22.84 87.69±20.50 84.86±23.60 0.05 
GH 70.83±22.82 87.50±20.52 85.86±24.20 0.02 
MH 79.43±27.42 90±12.45 90.86±17.96 <0.001 
PSC 67.29±17.59 90.41±7.99 92.67±20.15 <0.001 
MSC 52.34±10.01 69.87±4.47 69.27±10.59 <0.001 
*ANOVA 
**Mean ± SD 
physical functioning (PF), role limitations due to physical problems, bodily pain (BP), 
general health perception (GH), social functioning (SF), role limitations due to emotional 
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problems (RE), vitality (VT), and mental health (MH), mental subscale component (MSC), 
physical subscale component( PSC). 
 
 
 
 
 
 
